Clinical characteristics, treatment patterns and survival of individuals with adenocarcinoma of the stomach (ICD-10 C16) or the gastro-oesophageal junction (ICD-10 C15.5) in Germany - a study based on cancer registry data (VONKO-022)

Clinical characteristics, treatment patterns and survival of individuals with adenocarcinoma of the stomach (ICD-10 C16) or the gastro-oesophageal junction (ICD-10 C15.5) in Germany - a study based on cancer registry data (VONKO-022) - VONKOdb GC 2024

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035340

Enrollment

44000

Registered

2024-10-30

Start date

2024-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C16 C15.5

Interventions

Group 1: Retrospective analysis of cancer registry data of cases of adenocarcinoma of the stomach or gastro-oesophageal junction from the diagnosis years 2014-2023 (observational study)

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: - ICD-10 C15.5 and ICD-10 C15.5 - Histological type adenocarcinoma: ICD-O-3 8140-8149, 8160-8162, 8190-8221, 8260-8337, 8350-8551, 8570-8576, 8940-8941 - Diagnosis years 2014-2023 - For diagnosis place of residence in the federal state of the requested registry ‘residence-related cases’)

Exclusion criteria

Exclusion criteria: - Patients diagnosed with any other primary malignancy (except non-melanoma skin cancer; ICD-10 code C44) within 5 years prior to gastric/GOJ AC. - Cancer cases known to the registry based exclusively on i) a post-mortem certificate (DCO case), ii) a pathology or progress report, iii) a report on the tumour conference, or iv) a combination of the aforementioned notification types

Design outcomes

Primary

Measure	Time frame
Overall survival (OS) from diagnosis date for individuals with adenocarcinoma located in the stomach or the gastro-esophaeal junciton, overall, by site of tumour (C16, C15.5) and stratified by stage at diagnosis	—

Secondary

Measure	Time frame
Objective 1: To describe the demographic and clinical characteristics of all individuals with adenocarcinoma located in the stomach or the gastro-esophaeal junction, overall, by site of tumour (C16, C15.5) and stratified by stage at diagnosis Objective 2: To define and construct systemic anti-cancer therapy (SACT) line of therapy (LoT) algorithm for individuals with adenocarcinoma located in the stomach or the gastro-esophaeal junction Objective 3: To describe SACT, surgery and radiotherapy treatment patterns (including treatment intent, type of SACT/surgery received, radiotherapy details, time to first treatment, treatment duration, treatment free interval, reason for treatment end and surgery complications) of all individuals with adenocarcinoma located in the stomach or the gastro-esophaeal junction, overall and by site of tumour (C16, C15.5) and stratified by stage at diagnosis	—

Measure

Time frame

Objective 1: To describe the demographic and clinical characteristics of all individuals with adenocarcinoma located in the stomach or the gastro-esophaeal junction, overall, by site of tumour (C16, C15.5) and stratified by stage at diagnosis Objective 2: To define and construct systemic anti-cancer therapy (SACT) line of therapy (LoT) algorithm for individuals with adenocarcinoma located in the stomach or the gastro-esophaeal junction Objective 3: To describe SACT, surgery and radiotherapy treatment patterns (including treatment intent, type of SACT/surgery received, radiotherapy details, time to first treatment, treatment duration, treatment free interval, reason for treatment end and surgery complications) of all individuals with adenocarcinoma located in the stomach or the gastro-esophaeal junction, overall and by site of tumour (C16, C15.5) and stratified by stage at diagnosis

—

Countries

Germany

Contacts

Public ContactAnnika Waldmann

Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie

Annika.Waldmann@uksh.de+49 451 500 51240

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026